Prevail Innovative Wealth Advisors LLC Grows Stock Position in Merck & Co., Inc. $MRK

Prevail Innovative Wealth Advisors LLC boosted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 45.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 29,458 shares of the company’s stock after purchasing an additional 9,145 shares during the quarter. Prevail Innovative Wealth Advisors LLC’s holdings in Merck & Co., Inc. were worth $3,785,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Norges Bank acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $3,997,933,000. Wellington Management Group LLP grew its holdings in Merck & Co., Inc. by 14.8% during the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after acquiring an additional 11,156,354 shares in the last quarter. Cardano Risk Management B.V. purchased a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $1,012,530,000. Jennison Associates LLC purchased a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $585,192,000. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Merck & Co., Inc. by 37.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock valued at $1,973,983,000 after purchasing an additional 5,152,069 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Insider Transactions at Merck & Co., Inc.

In related news, EVP Chirfi Guindo sold 15,000 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total value of $1,965,000.00. Following the completion of the sale, the executive vice president owned 46,613 shares in the company, valued at $6,106,303. This represents a 24.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Richard R. Deluca sold 11,699 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the transaction, the executive vice president directly owned 110,167 shares in the company, valued at $14,501,282.21. The trade was a 9.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 137,923 shares of company stock worth $17,908,943 in the last three months. Corporate insiders own 0.17% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst sentiment improved: Daiwa Securities upgraded Merck to “outperform” and set a $143 price target, while Argus raised its target to $145 and maintained a “buy” rating. These targets imply additional upside from recent trading levels. Daiwa Securities upgrade
• Positive Sentiment: RSV expansion opportunity: The FDA and European Medicines Agency accepted supplemental applications for broader use of ENFLONSIA to prevent RSV in vulnerable young children. The regulatory reviews could expand Merck’s growth beyond oncology and help diversify the portfolio ahead of Keytruda’s future patent expirations. Merck RSV regulatory review article
• Positive Sentiment: Estimates edged higher: Erste Group raised its FY2026 earnings forecast for Merck to $2.75 per share from $2.70, broadly aligning with the $2.76 consensus estimate. The company also recently exceeded quarterly revenue and adjusted earnings expectations, reporting $16.61 billion in revenue.
• Positive Sentiment: Core business remains solid: Keytruda, oncology and animal health supported quarterly growth, while the company continues investing in its pipeline. Merck also declared its regular $0.85 quarterly dividend, equivalent to a $3.40 annualized payout.
• Neutral Sentiment: Vaccine-policy uncertainty: Reports that the administration may seek to split the MMR vaccine into separate shots could create headlines around the broader vaccine market, but experts say the proposal lacks scientific support and is unlikely to advance. MMR vaccine policy article
• Negative Sentiment: Repeated insider selling: EVP Richard R. Deluca sold roughly 45,000 shares across transactions from August 6 through August 12 for approximately $6.7 million. Although he retained a substantial position, the sales may weigh modestly on sentiment.
• Negative Sentiment: Longer-term risks persist: Analysts continue to flag falling estimates, a high valuation and upcoming patent expirations, particularly the eventual loss of Keytruda exclusivity. These issues could limit upside unless Merck’s pipeline and newer products offset the expected revenue pressure.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $133.10 on Thursday. The company’s fifty day moving average price is $124.94 and its 200 day moving average price is $119.64. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $135.05. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The firm has a market capitalization of $328.38 billion, a P/E ratio of 106.48, a P/E/G ratio of 5.62 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. Merck & Co., Inc.’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, sell-side analysts predict that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.6%. Merck & Co., Inc.’s payout ratio is 272.00%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $120.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Weiss Ratings cut Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday. Citigroup began coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price target for the company. JPMorgan Chase & Co. upped their price objective on Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Finally, Guggenheim upped their price objective on Merck & Co., Inc. from $145.00 to $146.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Fifteen research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Merck & Co., Inc. has an average rating of “Moderate Buy” and an average price target of $135.50.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.